Skip header and navigation

Refine By

396 records – page 1 of 40.

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.

https://arctichealth.org/en/permalink/ahliterature56626
Source
Scand J Infect Dis. 2002;34(8):610-4
Publication Type
Article
Date
2002
Author
K. Levie
I. Gjorup
P. Skinhøj
M. Stoffel
Source
Scand J Infect Dis. 2002;34(8):610-4
Date
2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Belgium
Comparative Study
Denmark
Dose-Response Relationship, Drug
Female
Hepatitis B - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis B vaccines - administration & dosage
Humans
Immunity - physiology
Immunization - methods
Immunization Schedule
Male
Reference Values
Research Support, Non-U.S. Gov't
Sensitivity and specificity
Single-Blind Method
Vaccines, Synthetic - administration & dosage
Abstract
An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. At 1 and 6 months after the full vaccination course there was a 100% seroprotection rate (anti-HBs > or = 10 mIU/ml) with the HBsAg/AS04 vaccine, compared with a 99% response rate with the licensed vaccine. The corresponding geometric mean titres were significantly higher for the novel vaccine compared to the standard vaccine: 15,468 and 2,745 mIU/ml at Months 7 and 12 vs. 6,274 and 1,883 mIU/ml, respectively. There was a higher prevalence of local symptoms with the adjuvant vaccine (90% of doses) than with the standard vaccine (48% of doses). However, these symptoms (pain, swelling and redness) were predominantly of mild-to-moderate intensity and resolved rapidly without treatment. A 2-dose regimen of the new HBsAg/AS04 adjuvant vaccine therefore compared favourably to the standard regimen in healthy young adults. It is anticipated that the simplified vaccination schedule may improve compliance and reduce costs.
PubMed ID
12238579 View in PubMed
Less detail

[2 vaccine dosages for basic prevention of whooping cough in children over 2 years of age?]

https://arctichealth.org/en/permalink/ahliterature34713
Source
Lakartidningen. 1996 Jul 10;93(28-29):2564
Publication Type
Article
Date
Jul-10-1996
Author
L. Gothefors
J. Storsaeter
Source
Lakartidningen. 1996 Jul 10;93(28-29):2564
Date
Jul-10-1996
Language
Swedish
Publication Type
Article
Keywords
Age Factors
Child, Preschool
Denmark
Humans
Immunization Schedule
Pertussis Vaccine - administration & dosage
PubMed ID
8801406 View in PubMed
Less detail

[A calendar of prophylactic inoculations in wide practical use]

https://arctichealth.org/en/permalink/ahliterature38630
Source
Zh Mikrobiol Epidemiol Immunobiol. 1988 Jan;(1):37-41
Publication Type
Article
Date
Jan-1988
Author
L M Chudnaia
A B Shekhter
L S Krasiuk
V G Oksiiuk
B N Fastovskaia
Source
Zh Mikrobiol Epidemiol Immunobiol. 1988 Jan;(1):37-41
Date
Jan-1988
Language
Russian
Publication Type
Article
Keywords
Antibody formation
Child
Child, Preschool
Comparative Study
Diphtheria Toxoid - immunology
Diphtheria-Tetanus-Pertussis Vaccine
Drug Combinations - immunology
English Abstract
Humans
Immunization Schedule
Immunization, Secondary
Infant
Measles Vaccine - immunology
Mumps Vaccine - immunology
Pertussis Vaccine - immunology
Poliovirus Vaccine, Inactivated - immunology
Rural Population
Tetanus Toxoid - immunology
Time Factors
Ukraine
Urban Population
Vaccination
Abstract
The validity of immunizations, made in due time in children aged up to 7 years in accordance with the approved immunization schedule, is analyzed in this work. The content of antibodies to diphtheria, tetanus and poliomyelitis antigens in children immunized in accordance with the old and new schedules has been studied. This study has revealed that the injection of adsorbed DPT vaccine to children aged 3-4 months induces fully valid immune response to all antigens under study. The level of measles and parotitis antibodies after the injections of measles and parotitis vaccines, introduced separately and simultaneously, has been measured. The simultaneous administration of these preparations did not decrease the levels of immunity to parotitis and measles.
PubMed ID
3259058 View in PubMed
Less detail

[Active immunization and state of health of children]

https://arctichealth.org/en/permalink/ahliterature44829
Source
Pediatr Akus Ginekol. 1967;5:7-8
Publication Type
Article
Date
1967
Author
B Ia Réznik
Source
Pediatr Akus Ginekol. 1967;5:7-8
Date
1967
Language
Ukrainian
Publication Type
Article
Keywords
Child
Humans
Immunity, Active
Immunization Schedule
Ukraine
PubMed ID
5611262 View in PubMed
Less detail

Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease.

https://arctichealth.org/en/permalink/ahliterature133348
Source
Can J Public Health. 2011 May-Jun;102(3):196-9
Publication Type
Article
Author
Jane E Schuler
W James King
Natalie L Dayneka
Lynn Rastelli
Evelyn Marquis
Zave Chad
Charles Hui
Author Affiliation
Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON. jschuler@cheo.on.ca
Source
Can J Public Health. 2011 May-Jun;102(3):196-9
Language
English
Publication Type
Article
Keywords
Canada
Child
Child, Preschool
Egg Hypersensitivity
Female
Humans
Immunization Schedule
Infant
Influenza A Virus, H1N1 Subtype
Influenza Vaccines - administration & dosage - adverse effects
Influenza, Human - prevention & control
Male
Prospective Studies
Safety Management
Abstract
In Canada, the pH1N1 influenza vaccine is recommended for children, particularly those less than 5 years of age or with chronic underlying disease. The pH1N1 vaccine, which contains residual allergenic egg white proteins, may pose a risk for vaccination of egg-allergic children.
To describe the outcome of pH1N1 influenza vaccine administration to egg-allergic children at risk for severe H1N1 disease.
Prospective observational cohort study. Children identified as at high risk for egg allergy and H1N1 influenza were vaccinated using a two-dose split protocol in a controlled medical setting. Children were given an initial test dose; if no reaction was noted, the remainder of the dose was administered and the children were followed for allergic reactions. Those who tolerated the split dose and required a second dose of vaccine were offered vaccination four weeks later as one injection.
Sixty-two egg-allergic children considered at high risk for H1N1 disease received the adjuvanted pH1N1 vaccine. Egg allergy was diagnosed both clinically by an allergist and using skin and/or serum IgE testing. Within one hour of immunization, 2 children developed hives, 1 had a vasovagal response and 1 had a hypo-responsive episode. Fourteen children received the second H1N1 dose and 1 developed erythema and itching. There were no anaphylactic reactions.
Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at risk for severe H1N1 influenza was safe when performed in a two-dose split protocol in a controlled medical setting.
PubMed ID
21714318 View in PubMed
Less detail

[Adoption of foreign children in Denmark. Health conditions in 83 families. I. Adopted children]

https://arctichealth.org/en/permalink/ahliterature40409
Source
Ugeskr Laeger. 1982 Jul 5;144(27):2033-7
Publication Type
Article
Date
Jul-5-1982

[Advantages and disadvantages of inactivated and live influenza vaccine].

https://arctichealth.org/en/permalink/ahliterature178960
Source
Vopr Virusol. 2004 Jul-Aug;49(4):4-12
Publication Type
Article
Author
Iu Z Gendon
Source
Vopr Virusol. 2004 Jul-Aug;49(4):4-12
Language
Russian
Publication Type
Article
Keywords
Adult
Aged
Allergens - immunology
Antibodies, Viral - blood
Child
Clinical Trials as Topic
Egg Proteins - immunology
Humans
Hypersensitivity - etiology
Immunity, Mucosal
Immunization Schedule
Influenza Vaccines - administration & dosage - adverse effects - immunology
Influenza, Human - epidemiology - prevention & control
Russia - epidemiology
Vaccination - adverse effects
Vaccines, Attenuated - administration & dosage
Vaccines, Inactivated - administration & dosage
Abstract
Published data related with comparison studies of safety, efficiency and some other properties of cold-adapted live influenza vaccine (LIV) and of inactivated influenza vaccine (IIV) are analyzed. LIV and IIV do not differ by systemic reactions after administration; however, it is not ruled out that there can be unfavorable reactions in vaccination of persons with allergy to the chicken-embryo proteins as well as in cases of persistence/reversion of cold-adapted strain observed in vaccination of persons with primary impairments of the immune system. There are no convincing data, up to now, on that LIV is superior to IIV in coping with influenza pandemics. The efficiency of LIV and IIV for children aged 3 years and more and for healthy adults is virtually identical. Additional controllable field comparative studies of LIV and IIV efficiency in immunization of elderly persons are needed. Limited data on LIV efficiency for children aged 2 months and more were obtained. The need in a 2-stage vaccination of all age group with the aim of ensuring responses to all 3 LIV components is, certainly, a LIV disadvantage. In case of IIV, the 2-stage vaccination is needed only for persons who were not ill with influenza. The intranasal LIV administration has, from the practical and psychological standpoints, an advantage before the IIV administration by syringe. The ability of LIV to protect from the drift influenza-virus variations could be its advantage before IIV; still, more research is needed to verify it. Transplantable cell lines meeting the WHO requirements could be an optimal substrate for the production of LIV and IIV. Children are the optimal age group for influenza prevention by cold-adapted LIV, whereas, IIV fits better for vaccination of adults and elderly persons.
PubMed ID
15293504 View in PubMed
Less detail

Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial.

https://arctichealth.org/en/permalink/ahliterature57618
Source
Dev Biol Stand. 1997;89:109-12
Publication Type
Article
Date
1997
Author
J. Taranger
B. Trollfors
N. Knutsson
Author Affiliation
Gothenburg University, Sweden.
Source
Dev Biol Stand. 1997;89:109-12
Date
1997
Language
English
Publication Type
Article
Keywords
Diphtheria Toxoid - adverse effects
Diphtheria-Tetanus Vaccine
Diphtheria-Tetanus-Pertussis Vaccine - adverse effects
Double-Blind Method
Humans
Immunization Schedule
Infant
Research Support, U.S. Gov't, P.H.S.
Sweden
Tetanus Toxoid - adverse effects
Toxoids - adverse effects - immunology
Vaccines, Combined - adverse effects
Whooping Cough - prevention & control
Abstract
In the Gothenburg study, 3,450 infants were randomly assigned to receive three subcutaneous injections of acellular pertussis vaccine consisting of peroxide-inactivated pertussis toxin with diphtheria and tetanus toxoids (DTP-toxoids) or DT-toxoids alone under blind conditions at three, five and 12 months of age. Safety of the vaccinations was assessed by direct contact with the families in the week following each injection. No serious vaccine-associated adverse reactions were observed, in either group. The frequency of fever and local reactions increased by dose. Redness and swelling were slightly but significantly more frequent in recipients of DTP-toxoids compared to the DT group.
PubMed ID
9272340 View in PubMed
Less detail

396 records – page 1 of 40.